Exelixis Announces Promising Phase 1b Data for Cobimetinib in Combination with Vemurafenib at ECC 2013

Exelixis (NASDAQ: EXEL ) today announced updated results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group (SIX: RO, ROG;